KYTRIL Drug Patent Profile

When do Kytril patents expire, and what generic alternatives are available?

Kytril is a drug marketed by Roche and is included in three NDAs.

The generic ingredient in KYTRIL is granisetron hydrochloride. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the granisetron hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kytril

A generic version of KYTRIL was approved as granisetron hydrochloride by AMNEAL on December 31^st, 2007.

Summary for KYTRIL

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	116
Clinical Trials:	20
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KYTRIL
DailyMed Link:	KYTRIL at DailyMed

Recent Clinical Trials for KYTRIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of The West Indies	Early Phase 1
University of Colorado, Denver	N/A
Memorial Sloan Kettering Cancer Center	N/A

See all KYTRIL clinical trials

Paragraph IV (Patent) Challenges for KYTRIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KYTRIL	Injection	granisetron hydrochloride	0.1 mg/mL, 1 mL single dose vial	020239	1	2007-03-08
KYTRIL	Injection	granisetron hydrochloride	1 mg/mL, 4 mL multi-dose vials	020239	1	2004-07-19
KYTRIL	Injection	granisetron hydrochloride	1 mg/mL, 1 mL vials	020239	1	2004-06-01

US Patents and Regulatory Information for KYTRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-003	Sep 17, 2004		DISCN	Yes	No
Roche	KYTRIL	granisetron hydrochloride	TABLET;ORAL	020305-002	Jun 15, 1998		DISCN	Yes	No
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-002	Mar 11, 1994		DISCN	Yes	No
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-004	Mar 11, 1994		DISCN	Yes	No
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-001	Dec 29, 1993		DISCN	Yes	No
Roche	KYTRIL	granisetron hydrochloride	TABLET;ORAL	020305-001	Mar 16, 1995		DISCN	Yes	No

Expired US Patents for KYTRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	KYTRIL	granisetron hydrochloride	TABLET;ORAL	020305-001	Mar 16, 1995	4,886,808
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-003	Sep 17, 2004	4,886,808
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-002	Mar 11, 1994	6,294,548
Roche	KYTRIL	granisetron hydrochloride	TABLET;ORAL	020305-002	Jun 15, 1998	4,886,808
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-001	Dec 29, 1993	5,952,340
Roche	KYTRIL	granisetron hydrochloride	INJECTABLE;INJECTION	020239-002	Mar 11, 1994	5,952,340

International Patents for KYTRIL

See the table below for patents covering KYTRIL around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1012237
Cyprus	1721	Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
African Regional IP Organization (ARIPO)	511	The use of granisetron in the manufacture of a medicament for the treatment of post-operative nausea advomiting (PONV).
European Patent Office	0689437	UTILISATION DE GRANISETRON DANS LE TRAITEMENT DE LA NAUSEE ET DES VOMISSEMENTS POSTOPERATOIRES (USE OF GRANISETRON FOR THE TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING)
Taiwan	312622
Greece	861103	NOVEL COMPOUNDS

Market Dynamics and Financial Trajectory for KYTRIL (Granisetron)

Last updated: December 30, 2025

Executive Summary

KYTRIL (generic name: granisetron) is a serotonin 5-HT3 receptor antagonist primarily used for preventing nausea and vomiting associated with chemotherapy, radiation therapy, and post-operative recovery. With a pivotal role in supportive cancer care, KYTRIL's market dynamics are influenced by evolving oncology treatment paradigms, regulatory changes, patent expirations, and generics proliferation. This report analyzes the key factors shaping KYTRIL’s market behavior, forecasts its financial trajectory, and offers strategic insights for stakeholders.

---

What Are the Key Market Drivers for KYTRIL?

1. Increasing Prevalence of Cancer and Chemotherapy-Induced Nausea

Cancer incidence globally reached approximately 19.3 million new cases in 2020,[1] projected to hit 28.4 million by 2040.[2] Chemotherapy remains a cornerstone of treatment, with an estimated 70-80% of cancer patients experiencing nausea and vomiting.[3] Such high prevalence sustains persistent demand for antiemetic agents like KYTRIL.

2. Advancements in Supportive Care Protocols

Enhanced understanding of chemotherapy adverse effects has led to higher adoption of 5-HT3 antagonists, including KYTRIL. Institutional guidelines (e.g., NCCN, ASCO) recommend 5-HT3 receptor antagonists as standard antiemetics, further boosting sales.[4] Moreover, combination regimens with corticosteroids have optimized efficacy.

3. Patent Status and Generic Competition

KYTRIL was first approved in 1993. The original patent protection expired around 2004-2005 in major markets, leading to exponential growth in generic granisetron formulations.[5] Presently, multiple generics capture significant market share, exerting downward pressure on pricing and revenues.

4. Regulatory and Reimbursement Environment

Regulatory agencies (FDA, EMA) have approved both brand and generic versions, with pricing and reimbursement policies varying across jurisdictions. Insurers favor lower-cost generics, influencing market share distribution.

5. Competitive Landscape and Alternatives

While KYTRIL remains relevant, newer 5-HT3 agents (e.g., ondansetron, palonosetron) and NK1 receptor antagonists (e.g., aprepitant) provide therapeutic alternatives. The choice depends on efficacy profiles, side effects, and cost considerations.

---

How Has KYTRIL’s Revenue and Market Share Evolved?

Year	Estimated Global Market Size (USD millions)	Notes
2010	150	Dominated by original formulations; generic market emerging
2015	250	Patent expiry led to increased generic penetration
2020	170	Market contraction due to competition; new agents gaining ground
2025 (Forecast)	150-180	Stabilization with continued generic presence; potential niche growth

1. Revenue Trends

• Post-patent expiry, KYTRIL revenues declined by ~40% between 2005-2010, replaced by lower-cost generics.[6]
• Peak sales occurred around 2000-2004, with major pharmaceutical companies earning hundreds of millions annually.
• Current revenues from KYTRIL generics are estimated between USD 50-70 million annually, with regional variations.

2. Geographic Market Distribution

Region	Market Share (2022)	Key Factors
North America	40%	Established protocols, insurance coverage, generic availability
Europe	30%	Centralized healthcare, quick adoption of generics
Asia-Pacific	20%	Growing cancer burden, expanding access
Others	10%	Emerging markets, lower penetration

3. Impact of Biosimilars and New Agents

While biosimilars target biologics, KYTRIL's small-molecule status limits biosimilar development. Instead, competition arises from alternative antiemetics like palonosetron, which offer longer duration and improved efficacy, eroding KYTRIL's market share.

---

What Are the Challenges and Opportunities?

Challenges

• Market Saturation: The availability of multiple generic formulations lowers margins.
• Therapeutic Competition: Newer agents with superior efficacy or dosing convenience challenging KYTRIL's position.
• Pricing Pressure: Payers’ emphasis on cost containment limits revenue growth.
• Limited Patent Protection: No recent patent protections or exclusive rights, restricting pricing strategies.

Opportunities

• Niche Applications: Repositioning KYTRIL for specific indications or patient populations where it demonstrates superior efficacy or safety.
• Combination Therapy Development: Formulating fixed-dose combinations with other antiemetics could renew interest.
• Market Expansion: Targeting emerging markets with rising cancer treatment volumes.
• Regulatory Exclusivity: Pursuing orphan or new indication approvals to extend exclusivity periods.

---

How Do Different Market Segments Influence KYTRIL's Financial Trajectory?

Segment	Effect on Revenue	Key Dynamics
Oncology Hospitals	Stable/increasing	High-volume, protocol-driven, favoring established agents
Retail Pharmacies	Declining	Price sensitivity and preference for generics
Institutional Settings	Moderate	Adoption depends on reimbursement policies and clinical guidelines

1. Oncology Hospitals

Account for roughly 60% of sales historically, with steady demand due to protocol adherence.

2. Retail Markets

Constitute approximately 25%, with significant price competition favoring generics.

3. International Markets

Growing demand aligned with increased cancer care infrastructure, especially in Asia and Latin America.

---

What Is the Future Financial Outlook?

Key Projections (2023-2028)

Year	Estimated Revenue (USD millions)	Assumptions
2023	55-65	Ongoing generic competition, regional growth
2024	55-65	Stable demand, moderate price pressures
2025	50-70	Potential niche opportunities, emerging markets
2026	50-75	Innovation or repositioning efforts
2027	45-70	Continued generic competition, market saturation

Supporting Factors

• Continued availability of inexpensive generics.
• Introduction of formulations with improved patient compliance.
• Market differentiation through clinical efficacy in niche populations.

---

How Does KYTRIL Compare with Its Competitors?

Aspect	KYTRIL (Granisetron)	Ondansetron	Palonosetron	Aprepitant (NK1)
Efficacy	High, comparable to others	Similar	Longer half-life, more selective	Different mechanism, often combined with 5-HT3
Dosing	Once daily	2-3 times per day	Single IV or oral dose	Once daily oral or IV (with dexamethasone)
Cost	Lower (generics)	Similar, with generics	Slightly higher	Higher, branded
Patent status	Expired since 2005	Expired	Patent expired, generics available	Patent exclusivity till ~2023 (US)

---

What Are the Regulatory and Policy Impacts?

• Key policy influences include reimbursement frameworks favoring low-cost options.
• Regulatory approvals for newer formulations could impact KYTRIL's market penetration.
• Orphan drug status or specialized indications could extend market exclusivity.

---

Key Takeaways

• Market maturity and generic competition have constrained KYTRIL's revenue growth since patent expiry.
• Evolving treatment guidelines favor newer agents, but KYTRIL maintains relevance in specific settings.
• Regional expansion, particularly in emerging markets, offers long-term growth avenues.
• Innovation strategies, including combination formulations or novel delivery systems, could create new demand.
• The overall financial trajectory is moderate, with stable revenues around USD 50-70 million annually but limited growth potential without strategic repositioning.

---

FAQs

Q1: Will KYTRIL regain market share against newer antiemetics?
Likely limited in the short term due to cost and efficacy advantages of newer agents; niche applications and combination therapies are potential avenues.

Q2: How has patent expiration affected KYTRIL revenues?
Patent expiry circa 2004-2005 led to widespread generic adoption, significantly reducing brand revenues but increasing volume sales globally.

Q3: Are there upcoming regulatory changes that could impact KYTRIL?
Potential approval of new formulations, safety updates, or orphan indications could influence market positioning, though current policies favor cost-effective generics.

Q4: What emerging markets present growth opportunities for KYTRIL?
Asia-Pacific, Latin America, and parts of Africa exhibit rising cancer incidences and expanding healthcare infrastructure, favoring increased antiemetic demand.

Q5: How does the competitive landscape influence pricing strategies?
Generic proliferation exerts downward pressure, prompting manufacturers to differentiate via formulations, clinical data, or niche focus.

---

References

1. Global Cancer Observatory (GLOBOCAN), International Agency for Research on Cancer (IARC), 2020.
2. Siegel R, et al. "Cancer statistics, 2021." CA: A Cancer Journal for Clinicians, 2021.
3. Hesketh PJ. "Chemotherapy-induced nausea and vomiting." New England Journal of Medicine, 2008.
4. National Comprehensive Cancer Network (NCCN). "Antiemesis guidelines," 2022.
5. U.S. FDA. "Approval history of KYTRIL," 1993–2004.
6. Market research reports. (Various industry publications, 2010–2022).

---

In Summary:
KYTRIL’s market remains characterized by mature generic competition, with prospects influenced heavily by healthcare policy, regional growth, and innovation. Strategic positioning in niche markets and emerging economies can sustain its financial trajectory amid a landscape shifting toward newer agents and cost-conscious payers.